- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01412450
Efficacity Study With the Protégé EverFlex Stent in Popliteal Lesions (DUR-POP)
30. september 2013 opdateret af: Flanders Medical Research Program
DURABILITY-POP Study - Physician Initiated Trial Investigating the Efficacy of the Implant of Protégé EverFlex Nitinol Stents in Popliteal Lesions
This study will assess the results up to 12 months with the Protégé EverFlex stent (ev3) in patients presenting with a narrowing or blocking at the level of the knee artery, which leads to a limited walking distance, rest pain or non-healing ulcers.
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
60
Fase
- Fase 4
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Antwerp
-
Bonheiden, Antwerp, Belgien, 2820
- Imeldaziekenhuis
-
Edegem, Antwerp, Belgien, 2650
- University Hospital Antwerp
-
-
East-Flanders
-
Dendermonde, East-Flanders, Belgien, 9200
- A.Z. Sint-Blasius
-
-
Flemish Brabant
-
Tienen, Flemish Brabant, Belgien, 3300
- Heilig-Hart Ziekenhuis
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
General Inclusion criteria
- De novo, restenotic or reoccluded lesion located in the popliteal artery, with or without superficial femoral artery involvement
- Patient presenting a score from 2 to 5 following Rutherford classification
- Patient is willing to comply with specified follow-up evaluations at the specified times
- Patient is >18 years old
- Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- Prior to enrollment, the guidewire has crossed target lesion
- Patient is eligible for treatment with the self-expanding nitinol EverFlex (ev3) stent
Angiographic Inclusion Criteria
- The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation
- The target lesion, visually estimated, has a maximal length of 14 cm and can be categorized as either a type A or B lesions according the TASC II guidelines
- Target vessel diameter visually estimated is >3.5mm and <7.5 mm
- There is angiographic evidence of at least one-vessel-runoff to the foot
Exclusion Criteria:
- Presence of another stent in the target vessel that was placed during a previous procedure
- Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis
- Previous by-pass surgery in the same limb
- Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
- Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
- Perforation at the angioplasty site evidenced by extravasation of contrast medium
- Patients with known hypersensitivity to nickel-titanium
- Patients with uncorrected bleeding disorders
- Aneurysm located at the level of the SFA and/or popliteal artery
- Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
- Life expectancy of less than twelve months
- Ipsilateral iliac treatment before the target lesion procedure with a residual stenosis > 30% or ipsilateral iliac treatment conducted after the target lesion procedure
- Use of thrombectomy, artherectomy or laser devices during procedure
- Any patient considered to be hemodynamically unstable at onset of procedure
- Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: nitinol stent
Protégé EverFlex stent
|
implantation of one Protégé EverFlex stent
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
primary patency
Tidsramme: 12 months post-procedure
|
primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without TLR within 12 months
|
12 months post-procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Technical success
Tidsramme: 1 day post-procedure
|
Technical success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex imaging
|
1 day post-procedure
|
Primary patency rate at 6-, 12-month follow-up.
Tidsramme: 6-, 12-month follow-up
|
Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without prior TLR are defined as being primary patent.
|
6-, 12-month follow-up
|
Clinical success
Tidsramme: 6-, 12-month follow-up
|
Clinical success at follow-up is defined as an improvement of Rutherford classification at 6-, 12-month follow-up of one class or more as compared to the pre-procedure Rutherford classification.
|
6-, 12-month follow-up
|
tent fracture rate at 12-month follow-up
Tidsramme: 12-month follow-up
|
Determined according the following classification on x-ray: Class 0 (no strut factures); Class I (single tine fracture); Class II (multiple tine factures); Class III (Stent fracture(s) with preserved alignment of the components); Class IV (Stent fracture(s) with mal-alignment of the components); Class V (Stent fracture(s) in a trans-axial spiral configuration)
|
12-month follow-up
|
Serious adverse events
Tidsramme: 1 year
|
Defined as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization.
|
1 year
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Marc Bosiers, MD, A.Z. Sint-Blasius
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2010
Primær færdiggørelse (Faktiske)
1. august 2012
Studieafslutning (Faktiske)
1. august 2012
Datoer for studieregistrering
Først indsendt
2. juli 2010
Først indsendt, der opfyldte QC-kriterier
8. august 2011
Først opslået (Skøn)
9. august 2011
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
1. oktober 2013
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
30. september 2013
Sidst verificeret
1. september 2013
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- FMRP-100702
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Perifer arteriel sygdom
-
Mayo ClinicTilmelding efter invitationAnatomi af GSV for Rescue Peripheral IV AccessForenede Stater
-
Universitaire Ziekenhuizen KU LeuvenUniversity of Pittsburgh; Sheba Medical Center; Mount Sinai Hospital, Canada og andre samarbejdspartnereUkendtTwin Reversal Arterial Perfusion SyndromeSpanien, Tyskland, Israel, Belgien, Holland, Canada, Forenede Stater, Østrig, Frankrig, Italien, Det Forenede Kongerige
-
University of MiamiRekrutteringTvilling til tvilling transfusionssyndrom | Tvilling; Komplicerer graviditet | Twin Reversal Arterial Perfusion Syndrome | Monokorionisk diamniotisk placenta | Monokorial monoamniotisk placentaForenede Stater
-
Boston Children's HospitalIkke rekrutterer endnuGraviditetsrelateret | Moderlige; Procedure | Fostertilstande | Twin Monochorionic Monoamniotic Placenta | Tvilling til tvilling transfusionssyndrom | Twin Reversal Arterial Perfusion Syndrome | Vasa Previa | In utero-procedure, der påvirker foster eller nyfødte | Chorion; Abnorm | ChorioangiomForenede Stater
Kliniske forsøg med nitinol stent
-
Flanders Medical Research ProgramAfsluttet
-
Korea University Guro HospitalAfsluttetKritisk lemmeriskæmi | Infrapopliteal arteriel okklusiv sygdomKorea, Republikken
-
Cook Group IncorporatedAfsluttetBugspytkirtel neoplasmer | Galdevejsneoplasmer | Gulsot, obstruktivForenede Stater
-
Medical Care Center Prof. Mathey, Prof. Schofer...Medtronic VascularAfsluttet
-
Abbott Medical DevicesBaim Institute for Clinical ResearchAfsluttetPerifer vaskulær sygdomForenede Stater
-
Cordis CorporationAfsluttetArterielle okklusive sygdommeDet Forenede Kongerige
-
Provascular GmbHBoston Scientific CorporationAfsluttetPerifere arterielle sygdomme | Overfladisk lårbensarteriestenoseTyskland
-
Chinese University of Hong KongLifetech Scientific (Shenzhen) Co., Ltd.AfsluttetPerifer arteriel sygdomHong Kong
-
W.L.Gore & AssociatesAfsluttetPerifere vaskulære sygdommeForenede Stater
-
Cordis CorporationAfsluttet